Dopavision is a Berlin-based company developing digital therapeutics for myopia. Nearsightedness (myopia) is a vision condition in which patients can see objects near to them clearly, but objects farther away are blurry.Dopavision raises Series A roundIn a recent development, the company announced that it has raised €12M in its Series A round of funding. The round was led by Seventure …
Spatial technology measures association between green space exposure, myopia
Using satellite imaging techniques, researchers were able to establish an association between green space exposure at school and the change in school-specific myopia prevalence. Even a relatively small increase in green space exposure was associated with a nearly 30% lesser risk for non-myopic children to develop myopia.
Santen and Sydnexis Execute an Exclusive Licensing Agreement for SYD-101, an Investigational Treatment for Progressive Childhood Myopia
Santen and Sydnexis have signed an exclusive licensing agreement for SYD-101, Sydnexis’ investigational proprietary low-dose atropine formulation for childhood myopia, for Europe, the Middle East, and Africa (EMEA). SYD-101 is currently undergoing a large multicenter phase 3 clinical trial, the STAAR study, in Europe and the US.
Sydnexis Secures $45 Million Series B Financing
Sydnexis, Inc. today announced the completion of a $45 million Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi. The financing will be used to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the …